A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Tsutomu TakeuchiYoshiya TanakaMitsuhiro RokudaHiroyuki IzutsuYuichiro KanekoMusashi FukudaDaisuke KatoPublished in: Modern rheumatology (2020)
Peficitinib was well tolerated in Asian patients with RA over a median of 2 years, with no observed dose or temporal dependency for AEs with prolonged administration.